Technical Analysis for GRAY - Graybug Vision, Inc.

Grade Last Price % Change Price Change
B 35.0 17.33% 5.17
GRAY closed up 17.33 percent on Friday, January 22, 2021, on 29 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Up
Historical GRAY trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bullish Other 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Older End-of-Day Signals for GRAY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Graybug Vision, Inc. Description

Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinical Medicine Diseases Macular Degeneration Ophthalmology Related Macular Degeneration Retina Glaucoma Nerve Diabetic Retinopathy Macular Edema Blindness Wet Age Related Macular Degeneration Diabetic Macular Edema Retinopathy Intravitreal Administration Macula Of Retina Intravitreal Injection

Is GRAY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 37.88
52 Week Low 12.5
Average Volume 116,968
200-Day Moving Average 0.00
50-Day Moving Average 26.55
20-Day Moving Average 28.54
10-Day Moving Average 29.91
Average True Range 2.88
ADX 30.48
+DI 36.11
-DI 12.88
Chandelier Exit (Long, 3 ATRs ) 26.36
Chandelier Exit (Short, 3 ATRs ) 31.54
Upper Bollinger Band 33.38
Lower Bollinger Band 23.70
Percent B (%b) 1.17
BandWidth 33.95
MACD Line 1.88
MACD Signal Line 1.42
MACD Histogram 0.4549
Fundamentals Value
Market Cap 734.28 Million
Num Shares 21 Million
Price-to-Sales 0.00
Price-to-Book 5.44
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 43.46
Resistance 3 (R3) 42.52 38.76 42.05
Resistance 2 (R2) 38.76 36.60 39.23 41.58
Resistance 1 (R1) 36.88 35.27 37.82 37.82 41.11
Pivot Point 33.12 33.12 33.59 33.59 33.12
Support 1 (S1) 31.24 30.97 32.18 32.18 28.89
Support 2 (S2) 27.48 29.64 27.95 28.42
Support 3 (S3) 25.60 27.48 27.95
Support 4 (S4) 26.54